Get the app!
Back to Companies

Elicio Therapeutics, Inc.

ELTXNasdaqCIK: 0001601485

Elicio Therapeutics, Inc. (ELTX) shows 14 recent insider filings from 11 insiders, with no open-market buying or selling. Haqq Christopher (See Remarks) is the most active by dollar volume, and the single largest transaction was $598.2K by Connelly Robert. All figures are drawn from official SEC Form 3, 4, and 5 disclosures and update as new filings arrive.

Total Volume
$2.4M
Purchases
$0
Sales
$0
Unique Insiders
11

Recent Insider Trades

14 loaded
Sep 2ELTX
Elicio Therapeutics, Inc.
Venkatesan JayDirectorAward$58.7K
Sep 2ELTX
Elicio Therapeutics, Inc.
WILSON KAREN JDirectorAward$58.7K
Sep 2ELTX
Elicio Therapeutics, Inc.
Nissenson AllenDirectorAward$58.7K
Sep 2ELTX
Elicio Therapeutics, Inc.
ADAMS JULIANDirectorAward$58.7K
Sep 2ELTX
Elicio Therapeutics, Inc.
RUFFOLO ROBERT RDirectorAward$58.7K
Sep 2ELTX
Elicio Therapeutics, Inc.
Ashe Carol GailDirectorAward$58.7K
Sep 2ELTX
Elicio Therapeutics, Inc.
Chudnovsky YekaterinaDirector, 10% OwnerAward$58.7K
Jul 17ELTX
Elicio Therapeutics, Inc.
Shah PreetamSee RemarksAward$194.7K
Jul 17ELTX
Elicio Therapeutics, Inc.
Haqq ChristopherSee RemarksAward$206.9K
Jul 17ELTX
Elicio Therapeutics, Inc.
DeMuth PeterChief Scientific OfficerAward$169.1K
Jul 17ELTX
Elicio Therapeutics, Inc.
Connelly RobertCEO, President and Director, DirectorAward$598.2K
Feb 3ELTX
Elicio Therapeutics, Inc.
Haqq ChristopherSee RemarksGrant$412.3K
Feb 3ELTX
Elicio Therapeutics, Inc.
Shah PreetamSee RemarksGrant$388.0K
Dec 10ELTX
Elicio Therapeutics, Inc.
DeMuth PeterChief Scientific OfficerExercise$3.2K

14 filings